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It is estimated that congestive heart failure affects 
cans and contributes to abou 
e United States (1). However, 
n society not only by shortenin 
duration of life, but also by worsening the quality of life with 
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chroaic symptoms such as yspnea and fatigue as well as 
angiote~s~o-converting enzyme inhibitor ena 
sents Ike resuki of serial 
ventricular dysfunction an 
lowed up for a maximum of 2 years. 
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The SOLVD was an international 
collaborative investigatton f heart failure involving 83 hos- 
pitals affiliated with 23 centers in the United States, Canada 
and Belgium. Detailed escriptions of the design and pri- 
mary findings of the SOLVD treatment and prevention trials 
have been published (6,10,11). The main aim of SOLVD was 
to compare the effect of enalapril and placebo on mortality. 
Several subsidiary analyses were specified, including the 
effects of treatment on the quality of life (10). Patients 
had an ejection fraction of 50.35, were 
and did not have s vere valvular heart 
apacitatin~ or unstable angina pectoris, 
infarction within the past mont 
or serum ~reati~~~e >2.5 
ith symptoms of heart 
requiring treatment with di alis or diuretic drugs entered 
the treatment trial and 42 patients with minimal or n 
symptoms of heart failure ered the preveatio~ trial. A 
patients were randomly allocated to receive enala~r~~ 
(z 10 mg twice a day) or placebo. The study was approved by 
the institutional review board at each participating hospital, 
an provided informed consent at entry. 
assessment. Quality of life was assessed in 
SOLVD by two methods. In the main trials, a short, self- 
administered quality of life questionnaire was completed by 
5,025 of the randomized cohort. The SOLVD protocol 
specified that the questionnaire b  completed by all patients 
enrolled in the treatment trial and by those patients entering 
the prevention trial during the first 27 months of its $I-month 
recruitment period. Patients were asked to complete the 
questionnaire, an approximately 20.min task, at ~Rdorni~~- 
tion and again at6 weeks, I year and 2 years of follow-up. 
Contained within the questionnaire were 14 scales, ex- 
cerpted from previously validated instruments, addressing 
the following seven components of quality of life: I) physical 
functioning (vigor [ 121, activities of daily living [13]), 
2) emotional distress (anxiety [ 121, depression [ 12]), 3) social 
health (social functioning 1131, satisfaction with social life 
t 141), 4) intimacy [131,5) life satisfaction (general satisfaction 
]14], current life situation (151, hopefulness [the difference 
between future life situation and current life situation] [ 151). 
6) perceived health (interference with activities [ 14]), general 
health perception [14]), and 7) productivity or job perfor- 
mance 1131. Additionally, one question assessed the extent 
of dyspnea. 
In a substudy, 308 patients from 5 of the 23 SOLVD 
centers underwent detailed assessment of psychosocial, 
physical and intellectual functioning by a trained psycholo- 
gist at baseline (16) and periodically thereafter. Follow-up 
data from this substudy are not included herein and will be 
the subject of a future report. 
S&&XII methods. The analysis of serial responses to
the quality of life questionnaire was limited to patients with 
intact baseline r sponses. Using the SAS statistical package 
(17), least square means were 
(treatment or preventions an 
placebo) for each of the 
whether the treatm consistent across all kveis 
Among participants in the treatment trial. significantly 
better quality of life was noted the e~a~a~~~ group at two 
follow-up intervals (6 weeks au 1 year) in scales assessing 
social fuRctioni~g and nea. Better quality 
treatment trial partici was also observe 
follow-up interval for scales assessing activ 
living, general life satisfaction, general health perception and 
productivity. Among patients in the prevention trial, quality 
of life was better with enalapril with regard only to social 
functioning at the &week follow-up. Among patients in the 
combined treatment and prevention trials, quality of life was 
better with enalaprii at two consecutive follow-up intervals 
only in scales assessing social functioning and dyspned (Fig. 
I). Otherwise, no significant differences in quality of life 
were noted between the plac bo and e~a~a~ri~ g oups. 
Intact responses to the quality of life quest~o~~a~re were 
obtained in84% of patients at the 6-week follow-up, 73% at 
the l-year follow-up and 59% at he 2-year follow-up inter- 
val. Although data were unavailable in me patients be- 
cause of death during the follow-up (1% at 6 weeks, 
9% at 1 year and 17% at 2 years), most missing data were due 
to failure of surviving patients o answer individual questions 
or complete he entire questionnaire (15% at 6 weeks, I8% at 
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ata All chhers uality of Life Data Quality of Life Data 
can age (yr) 
em weight (kg1 
em ejection fraction (Q) 
ear heart rate (beaas/min) 
Race (%I 
While 
Wlack 
r 
N CHF dim (9) 
il 
II 
111 
1v 
Disease history (c/o) 
lschemic heart disease 
yocardial infarction 
Current smoker (%) 
Current angina (%) 
Current atrial fibrillation (%) 
CT ratio ~0.50 (%) 
Drug therapy (%) 
Digitalis 
Diuretic drugs 
Any vasodilator 
61.9 
76.5 
24.9 
824.8 125.2 123.1 125.6 124.8 125.8 
76.5 77.3 76.0 78.1 78.0 77.8 
79.9 80.5 79.5 75.2 7%.8 74.7 
80. I 81.1 75.0 88.5 89.2 88.5 
SO. 1 61.5 
15.8 27.9 
4.1 10.6 
87.7 
8.9 
3.3 
87.9 
8.7 
3.2 
84.5 
10.7 
4.7 
Ii.3 
57.0 
30.3 
8.4 
t3.s 
s7.7 
26.0 
2.9 
64.9 
32.9 
0.2 
0.0 
60.1 
33.7 
0.2 
0.0 
47.1 
32.9 
0.0 
0.0 
72.4 70.3 70.2 83.0 83.4 63.2 
65.0 66.7 61.5 80.2 81.1 79.0 
41.2 42.3 53.8 35.6 37.2 36. I 
26.8 24.3 31.7 14.5 14.9 86.2 
87.7 18.9 17.3 10.6 9.0 8.8 
21.7 22.8 19.2 24.3 23.5 22.9 
39.2 36.2 33.7 34.7 33.7 33.3 
6.1 11.6 7.7 3.8 3.1 4.7 
56.0 57.5 54.8 38.8 38.8 41.8 
68.6 65.4 66.3 13.3 11.8 12.4 
84.9 85.4 94.2 18.7 19.2 13.2 
56.6 54.5 54.8 43.7 45.1 49.6 
CHF = congestive heal1 failure; CT = cardiothoracic; NW-IA = New York Hean Association. 
1 year and 24% at 2 years). 
there was any §tat~§t~cal~y s 
enalapril groups for reaso 
found. 
However, a bias in respon 
questionnaire related to severit 
was noted (Fig. 2). 
trends toward a grea 
among pdtients with increasing severity of congestive heart 
failure as assessed by New York Heart Association func- 
tional class. This trend reached a high level of statistical 
in ent trial at the G-wee 
ter 
e active study drug enala 
quality of life scales asses 
t in 6 scales (activities 
Analysis of serial responses to a brief quality of life 
questionnaire among patients enrolled in the SC&V 
ment and prevention trials showed several modest benefits 
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seventies Trial 
Placebo ElldQWil Placebo 
Content Area Scales NO. No. ean No. ean -._ 
physicid functioning 
6 weeks 
I year 
y living (l-411: 
6 weeks 
I year 
6 weeks 
I year 
6 weeks 
I year 
2 years 
Satisfaction with so&d life (l-5) 
line 
6 weeks 
I year 
2 ye&m 
lnti ~2-l~~$ 
line 
6 weeks 
6 weeks 
iyclv 
2 years 
F life situation (-9-+9)t 
iii 
6 weeks 
1Yew 
2 years 
1,123 
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781 
587 
1,211 
1. 
1,183 
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811 
6s4 
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1. 
1. 
852 
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iJ96 
1. 
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12.23 
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12. 
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I .76 
1. 
I. 
I. 
2.33 
2.19 
2.19 
2.07 
3.03 
2.83 
6.00 
6.03 
6.32 
6.54 
-0.06 
-O.lql 
-0.2@J 
-0.36 
8.83 
8.35 
8.26 
8.71 
1.211 
1. 
924 
723 
2.30 
2.17 
2.13 
2.12 
1.2ll 3.04 
1.103 2.81 
925 2.83 
722 2.80 
5.94 
6.28 
6.37 
6.55 
672 -0.44 
7. 
7. 
7.73 
7.23 
I.31 
1.24 
1.27 
1.26 
4.46 
4.25 
4.43 
4.49 
4.42 
4.34 
4.56 
4.45 
2.76 
2. 
2.70 
2.14 
1,267 
1.142 
2.79 
2.10 
2.72 
2.65 
6.62 I.264 6.69 
6.81 1.142 6.71 
6.94 I ,127 6.84 
?.Cj 879 7.06 
0.15 1,251 0.15 
-0.0711 1.125 0.02 
-0.05 993 0.03 
-0.19/J 8.57 -0.24 
Perceived healaht 
Bnretierence with aclivilics (P-6) 
6 weeks 
9 year 
2 yrws 
yspnea UK5E 
Beseliae 
6 weeks 
I year 
2 yars 
I.197 2.71 B ,246 2.26 
B ,083 2.511 1,118 2.17 
908 2.40 1,OP1 2.05 
712 2.38 854 2.09 
n,wi 3.53 I,249 3.15 
I.092 3.36 1,119 3.04 
912 3.33 I.016 2.99 
719 3.31 864 3.03 
17.3 13.M 342 MS% 358 94.59 
144 14.34 x34 15.42 2’30 IS.45 
802 15.63 243 IS.51 26s 15.81 
89 14.72 205 16.01 218 15.99 
l,267 X%4 
1,139 3.08 
I,036 3.00 
897 3.02 
1,270 8.66 
8,142 I .56 
1.042 1.56 
1.53 
ata shown for 6 weeks and 1 and 2 years are means that adjust for baseline. treating all clinics as equal in size; p values are on a per comparison basis and 
are not adjusted for multiple atdyses. Wigher scores imph better quality of life. Shver scores imply better qua!ity of life. IIBasGte interaction present (p value 
**p < 0.001 (placebo vs enalapril). Numbers in parentheses indicate the range of possible values on the paflicular scale. 
score implies better quality of life. B-rer bars indicate standard 
errors I 
6 1Yr PYr 
I-O.ow3 p-O.02 pN.S 
rather to be a brie, k 
st suitable as a rapid 
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2. Relation of missing quality of life data to New York 
sseclation (NYHA) congestive h art fa 
treatment trial (A) and the prevention trial 
interval in the treatment trial. 
of a healthy control grou 
worsening severtty o
heart failure. Thus, it seems likely that he 
questionnaire should have detected significant differences in 
uality of life in SOEVD participants during treatment with 
lacebo r e~ap~ if differences truly existed. 
over phenomenon” may have existed, such that patients 
expended considerable intellectual energy to respond to the 
baseline questionnaire and then catried over the same re- 
sponses to +he follow-up questionnaires a a matter of 
convenience. Moreover, some of the scales may have as- 
sessed character t aits developed over a lifetime and thus 
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from the differential mortality rates in enalaprii and placebo 
groups, they represent the extreme case in which the 
tality information is incorporated fully into the analysi 
pants in the treatment trial). The mag~i%~d~ of the b 
the patients in the treatment trial cannot 
certainty because of the extent of missing data, but it would 
appear to be quite modest. 
None of the analyses howed a significant negative im- 
management of patients with §ym~tomatic left ve~t~c~~a~ 
dysfunction for whom there are no CQ~t~ai~dicat~ons. 
among asymptomatic patients with left ventricular dysfunc- 
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